Welcome to chemicalbook!
+1 (818) 612-2111
Inquriy
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

RFQ
skype
MY Account
Top
Postion:Product Catalog >Biochemical Engineering>Inhibitors>Proteases>Proteasome inhibitors>Carfilzomib
Carfilzomib
  • Carfilzomib
  • Carfilzomib
  • Carfilzomib
  • Carfilzomib
  • Carfilzomib

Carfilzomib

Price Get Latest Price
Package 25Kg/Bag
Min. Order: 2Kg/Bag
Supply Ability: 20 tons
Update Time: 2024-06-04

Product Details

Product Name: Carfilzomib CAS No.: 868540-17-4
Min. Order: 2Kg/Bag Purity: 0.99
Supply Ability: 20 tons Release date: 2024/06/04

Product Information

Product name

Carfilzomib

CAS No.

868540-17-4

Molecular Formula

C40H57N5O7

Molecular Weight

719.922

Molecular Structure

Article illustration

Quality Standard

98% up by HPLC

Appearance

White powder

COA of Carfilzomib

ITEM

SPECIFICATION

RESULTS

Appearance

White powder

Complies

Identification

IR, UF, HPLC. In comparison with Carfilzomib RS

Complies

Melting point(the Range of temperature≤4 )

230 

230 

Solubility

slightly soluble in water and in alchohol, freely soluble in acetic acid and in methanol

Complies

Heavy metal

0.001% - 0.002%

Complies

Loss on Drying

≤1.0%

0.23%

Residue on ignition

≤1.0%

0.08%

Residual organic solvents

Ranged I and II toxic class

Complies

Total impurities

≤1.0%

0.54%

Assay (by HPLC)

≥ 98.0%

98.96%

Conclusion

The results conforms with enterprise standard.

Usage

Studies have shown that lenalidomide combined with dexamethasone plus carfilzomib has unprecedented efficacy in the treatment of relapsed multiple myeloma. The three-drug combination therapy for patients with first relapsed multiple myeloma has a progression-free survival of more than two years, which confirms the efficacy of the three-drug combination. Although the interim data analysis of this trial did not yield median overall survival in either group, the addition of carfilzomib trended toward longer overall survival (73.3% in the added carfilzomib group and 65% in the control group). ), this test result did not exceed the statistical range set by the statistician at the beginning of the experiment. More importantly, the addition of carfilzomib did not significantly increase toxicity, and the quality of life score was also higher than that of the control group. Another important information brought by this trial is that the total effective rate of the three-drug combination is significantly higher than that of the two-drug combination, 87.4% and 66.9% in the two groups, respectively; the complete remission rate of the three-drug combination is more than 3 times higher, and the two Groups were 31.8% and 9.4%, respectively. By adding carfilzomib to the gold standard for the treatment of multiple myeloma, unprecedented duration of response was seen without increased toxicity, which holds great promise for relapsed and high-dose preconditioning patients. These results may establish a new standard of care for the treatment of relapsed and high-dose preconditioning patients.

Article illustration

Company Profile Introduction

Sinoway Industrial co., ltd. was established in 1987 in Xiamen, China, and now has been a leading group specialized in research, development, custom manufacturing and trading of pharmaceutical intermediates, APIs, health and food supplements, cosmetic raw materials, herbal extracts, polypeptides and prostaglandin derivatives, etc.. We have passed ISO9001:2015. With qualified products, competitive price and excellent service, we have received great reputation of our customers from all over the world, including Southeast Asia, Europe, North America, South America, Middle East and other countries. We have over 20 years good partners in Japan、Korea and Switzerland. Sinoway has a professional R&D team. We have built close cooperative relationships with many research institutes and universities in China. Moreover, Sinoway combines market analysis with technology, providing new business trends to our clients. In addition, we have very close cooperation relationships with many Chinese pharmaceutical factories. These pharmaceutical manufacturers have GMP regulated workshops, advanced production and testing equipments, first-class QC labs and a production team with rich experience. We can supply various Active Pharmaceutical Ingredients and finished products which meet EP/USP/BP standards. Chinese GMP, EU-GMP, COS/CEP certificates with DMF documents are available, and many products have been approved by FDA. We believe that quality and innovation are vital for an enterprise. Adhering to the business philosophy of integrity and win-win cooperation, Sinoway is looking forward to have a bright future with you together.

You may like

Recommended supplier

Product name Price   Suppliers Update time
$0.00/1KG
VIP1Y
Hangzhou Hyper Chemicals Limited
2024-05-09
$0.00/25kg
VIP1Y
Shaanxi Haibo Biotechnology Co., Ltd
2023-09-07
$0.00/10g
VIP4Y
WUHAN FORTUNA CHEMICAL CO., LTD
2023-01-11
$0.00/1KG
VIP2Y
Henan Aochuang Chemical Co.,Ltd.
2022-10-18
$9.90/10g
Shanghai Biolang Biotechnology Co., Ltd.
2022-02-10
$15.00/1KG
Zhuozhou Wenxi import and Export Co., Ltd
2021-07-10
$198.00/250mg
VIP5Y
BOC Sciences
2020-05-13
$0.00/1ASSAYS
Beijing Yibai Biotechnology Co., Ltd
2019-08-26
$7.00/1kg
VIP6Y
Career Henan Chemical Co
2018-12-18
$15.00/1KG
Zhuozhou Wenxi import and Export Co., Ltd
2021-07-09
  • Since: 1996-07-16
  • Address: Fujian China ,16F, Huicheng Comm. Complex, 839 Xiahe RD.
INQUIRY